ADMS - アダマス・ファ―マシュ―ティカルズ (Adamas Pharmaceuticals Inc.)

ADMSのニュース

   Squarepoint Ops LLC Sells 39,923 Shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)  2021/11/27 10:08:47 Transcript Daily
Squarepoint Ops LLC decreased its stake in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) by 69.5% during the second quarter, Holdings Channel.com reports. The institutional investor owned 17,561 shares of the specialty pharmaceutical companys stock after selling 39,923 shares during the quarter. Squarepoint Ops LLCs holdings in Adamas Pharmaceuticals were worth $93,000 at the end of the most []
   Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer  2021/11/23 13:00:00 Intrado Digital Media
ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021.
   New Zealands Counties Energy Partners with GE Digital for its Digital Utility Transformation  2021/11/22 15:00:00 Kwhen Finance
   Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Short Interest Down 44.9% in October  2021/11/19 10:18:42 Transcript Daily
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was the target of a significant drop in short interest in October. As of October 29th, there was short interest totalling 881,300 shares, a drop of 44.9% from the October 14th total of 1,600,000 shares. Based on an average daily volume of 1,130,000 shares, the short-interest ratio is currently 0.8 days. []
   Adamas Pharmaceuticals (NASDAQ:ADMS) Lowered to Market Perform at Northland Securities  2021/11/17 12:36:41 Transcript Daily
Northland Securities lowered shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from an outperform rating to a market perform rating in a research report released on Wednesday, The Fly reports. ADMS has been the topic of several other research reports. Piper Sandler lowered Adamas Pharmaceuticals from an overweight rating to a neutral rating and boosted their price target []
   Adamas to Present at Upcoming William Blair Biotech Focus Conference  2021/07/08 20:02:00 Business Wire
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 1:00 pm Eastern Time. The fireside chat will be broadcast live from the investor relations sectio
   Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options  2021/07/08 13:50:51 Yahoo Finance
Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options Yahoo Finance
   Adamas Pharmaceuticals: Share Price Range-Bound Despite Steady Revenue Growth  2021/07/06 12:17:00 Seeking Alpha
   Multiple Sclerosis Drugs Market Size 2021-2028 | To Reach USD 41.99 Billion by 2028, Exhibiting a CAGR of 6.3 % - Stocks News Feed  2021/07/05 09:37:52 Stocks News Feed
Pune, India, July 05, 2021 (GLOBE NEWSWIRE) The global multiple sclerosis drugs market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to discover innovative and effective therapies for the treatment of this immune disorder. For instance, in December 2020, Adamas Pharmaceuticals, Inc. declared the results of its Read More »Multiple Sclerosis Drugs Market Size 2021-2028 | To Reach USD 41.99 Billion by 2028, Exhibiting a CAGR of 6.3 %
   Adamas to Present at Upcoming SVB Leerink CNS Forum  2021/06/23 20:42:00 Business Wire
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the company will present Whats Happening in Parkinsons Disease & the GOCOVRI Opportunity at the SVB Leerink CNS Forum on Tuesday, June 29th at 1:10 pm Eastern Time. The presentation will be broadcast live from the investor relations section of the Ad
   Adamas to Present at Upcoming William Blair Biotech Focus Conference  2021/07/08 20:02:00 Business Wire
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 1:00 pm Eastern Time. The fireside chat will be broadcast live from the investor relations sectio
   Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options  2021/07/08 13:50:51 Yahoo Finance
Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options Yahoo Finance
   Adamas Pharmaceuticals: Share Price Range-Bound Despite Steady Revenue Growth  2021/07/06 12:17:00 Seeking Alpha
   Multiple Sclerosis Drugs Market Size 2021-2028 | To Reach USD 41.99 Billion by 2028, Exhibiting a CAGR of 6.3 % - Stocks News Feed  2021/07/05 09:37:52 Stocks News Feed
Pune, India, July 05, 2021 (GLOBE NEWSWIRE) The global multiple sclerosis drugs market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to discover innovative and effective therapies for the treatment of this immune disorder. For instance, in December 2020, Adamas Pharmaceuticals, Inc. declared the results of its Read More »Multiple Sclerosis Drugs Market Size 2021-2028 | To Reach USD 41.99 Billion by 2028, Exhibiting a CAGR of 6.3 %
   Adamas to Present at Upcoming SVB Leerink CNS Forum  2021/06/23 20:42:00 Business Wire
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the company will present Whats Happening in Parkinsons Disease & the GOCOVRI Opportunity at the SVB Leerink CNS Forum on Tuesday, June 29th at 1:10 pm Eastern Time. The presentation will be broadcast live from the investor relations section of the Ad

calendar